Alphyn is a novel biotherapeutics company operated by experienced pharmaceutical industry scientists and business executives. It has a product pipeline developing well validated products focused on $40B inflammatory and rare diseases of the skin. Alphyn’s lead product is focused uniquely to treat all causes of Atopic Dermatitis (AD), both infected AD, with the expectation it will be the only topical approved to kill AD’s bacterial complications including the drug resistant MRSA bacteria, and non-infected AD, with an impressive safety and side effect profile. Alphyn has obtained an accelerated development advantage with a Phase 1 waiver utilizing extensive safety data. Alphyn has a way forward to 5 years of FDA exclusivity and potential 10 years FDA exclusivity for AD with FDA QIDP designation. Preclinical data shows an excellent efficacy and safety profile. The company has an impressive patent application portfolio. Alphyn is currently in Phase 2a clinical trial.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Dermatology
Lead Product in Development:
Drug product to treat atopic dermatitis, both infected & non-infected, with promising safety profile
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
